Rationale: A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies represent potential radiotracers for cardiovascular molecular imaging. Vascular cell adhesion molecule-1 (VCAM1) constitutes a relevant target for molecular imaging of atherosclerotic lesions.
administration. Nanobodies constitute a promising new class of radiotracers that might adhere to these conditions. Nanobodies are derived from unique heavy chain-only antibodies that are by nature present in camelids and represent the smallest possible (10 -15 kDa) functional immunoglobulin-like antigen-binding fragment. Nanobody-based tracers targeting cancer antigens epidermal growth factor receptor, carcinembryonic antigen, or human epidermal growth factor receptor 2 (HER2) with (sub-)nanomolar affinities have already proven their ability to generate highly specific contrast images in mouse tumor models. [2] [3] [4] [5] The inflammatory process leading to the development of vulnerable atherosclerotic lesions is characterized by extensive recruitment of monocytes and lymphocytes into the arterial wall. 6 Several endothelial adhesion molecules are implicated in the process of leukocyte rolling, firm adhesion, and transmigration, such as E-and P-selectins, vascular cell adhesion molecule-1 (VCAM1), and intercellular adhesion molecule-1 (ICAM1). 7 VCAM1 is a receptor of the immunoglobulin family that binds to very late antigen-4 (VLA4) present on the surface of leukocytes. 8 As active inflammation characterized by leukocyte infiltration is recognized as a major criterion for defining a vulnerable plaque, 9 the adhesion molecule VCAM1 is a relevant molecular target for noninvasive detection of such lesions. Indeed, VCAM1 expression was observed at the level of the luminal endothelium as well as on neovessels of advanced lesions, on macrophages, and on activated smooth muscle cells. 10 -12 Therefore, molecular probes targeting VCAM1 have been evaluated by our group and others either for nuclear, magnetic resonance, fluorescent, or ultrasound in vivo imaging. [13] [14] [15] [16] In the present study, our objectives were to generate and evaluate nanobody-based radiolabeled tracers for preclinical imaging of atherosclerotic plaques. Specifically, we describe (1) the generation and full in vitro characterization of cross-reactive mouse and human VCAM1-targeted nanobodies; (2) their 99m Tc-radiolabeling; and (3) their thorough assessment as tracers for noninvasive in vivo nuclear molecular imaging of atherosclerotic lesions in ApoE-deficient (ApoE Ϫ/Ϫ ) mice.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Nanobody Generation and Production
VCAM1-targeting nanobodies were generated largely after published methods. 17 Specifically, a dromedary was immunized with both mouse and human recombinant VCAM1 proteins (RnD Systems), blood lymphocytes were isolated, and RNA was purified. The variable domains of the heavy chain-only antibodies (V HH s or nanobodies) were amplified using a 2-step RT-PCR method and cloned in frame with M13 bacteriophage gene 3. Nanobodies were phage-displayed and used in biopannings on immobilized immunogens. Crude bacterial extracts containing soluble nanobodies were used to select individual VCAM1 binders based on a positive signal in ELISA and in flow cytometry on tumor necrosis factor alpha (TNF)␣-stimulated bEND5 cells. After sequencing, selected anti-VCAM1 and irrelevant control cAbBcII10 nanobodies were produced as hexahistidine-tagged proteins in Escherichia coli and purified, as described previously. 18 
In Vitro Evaluation of Unlabeled Nanobodies

Cell Lines
The mouse endothelial cell line bEND5 (ECACC) was cultured in supplemented DMEM medium and the human umbilical vein endothelial cells (HUVEC) in supplemented EndoGro basal medium (Millipore). VCAM1 expression was induced by stimulation with 10 ng/mL TNF␣ during 18 hours.
Flow Cytometry
TNF␣-stimulated (10 5 ) and unstimulated cells were incubated either with PE-labeled anti-VCAM1 monoclonal antibody (mAb) (antimouse from Abcam; anti-human from RnD Systems) or sequentially with 1 g nanobody, 1 g anti-His-tag mAb (Serotec), and 200 ng PE-labeled rat anti-mouse IgG1 (BD Biosciences). Binding was measured on a FACS Canto II analyzer (BD Biosciences) and data were analyzed with FlowJo software (TreeStar).
Thermal Stability
T m values (unfolding temperatures) were obtained on a J-715 spectropolarimeter (Jasco, Easton, MD), as previously described. 4 
Surface Plasmon Resonance-Based Affinity Evaluation
Nanobodies affinity for recombinant human and mouse VCAM1 was determined by surface plasmon resonance (SPR) analysis on a Biacore 3000 apparatus. Recombinant mouse ICAM1 (RnD Systems) was used as a negative control. Recombinant proteins were immobilized on a CM5 sensor chip (Biacore) according to the manufacturer's instructions. A 2-fold dilution series of nanobodies from 50 -1 nmol/L were tested. Affinity constants were determined using a 1:1 standard association model fit (BIAevaluation software). Nanobodies were radiolabeled with 99m Tc using the tricarbonylmethod, as described elsewhere. 3 Radiochemical purity was assessed immediately after labeling, after 6 hours at 20°C in phosphatebuffered saline (PBS) and in mouse blood 3 hours after injection. In the latter case, 100 L of sampled whole blood was centrifuged and plasma was filtered using a Nanosep 10 kDa Omega Membrane. Radiochemical purity was determined by reverse-phase highperformance liquid chromatography (HPLC), using a C4 column eluted with a phosphate-buffered saline/trifluoroacetic acid gradient mobile phase. Radioactivity was monitored using a radiodetector (␥-RAM Model 4, LabLogic).
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In Vitro Evaluation of 99m
Tc-Labeled Nanobodies Cells (250ϫ10 3 bEND5) were plated in 24-well plates and stimulated 18 hours with 10 ng/mL TNF␣. Five nanomoles per liter of each 99m Tc-nanobody was incubated in 0.5 mL PBS ϩ1% human serum albumin for 1.5 hours at 37°C. Competition studies with a 500-fold excess of unlabeled nanobody were conducted to assess the specificity of the binding. After washing, bound 99m Tc-nanobody was collected and counted in a ␥-counter (Canberra Packard). Nonspecific binding to the well was subtracted, and results were normalized to the TNF␣-negative condition.
Animal Model and Processing of Aortas
All animal experiments were approved by the Grenoble Research Center of the Army Health Services (CRSSA) committee. Female 35Ϯ2 week-old (meanϮSD) ApoE Ϫ/Ϫ and control C57Bl/6J mice were used (Charles River). ApoE Ϫ/Ϫ mice (nϭ47) were fed a Western diet containing 0.25% cholesterol (Safe) for 18 weeks, whereas control mice (nϭ15) remained on a standard chow diet.
Biodistribution
Each anti-VCAM1 nanobody was evaluated in 3 ApoE Ϫ/Ϫ mice except 99m Tc-cAbVCAM1-5 (nϭ6), which was also further evaluated in control C57Bl/6J mice (nϭ4).
99m Tc-cAbBcII10 was evaluated as a negative control in both ApoE Ϫ/Ϫ (nϭ4) and control mice (nϭ5). Two hours after 99m Tc-radiolabeled nanobody administration (67Ϯ4 MBq i.v.), single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition was performed in all animals (nanoSPECT, Bioscan, see below). Mice were then euthanized and aortas were cut into 12 segments. A lesion-extension index was attributed to each segment as shown in Online Figure I : (Ϫ) no lesion (control segments), (ϩ) lesion covering up to 50% of the arterial segment length, (ϩϩ) lesions covering Ͼ50% of the arterial segment length, and (ϩϩϩ) lesions extending over the whole segment length. Biodistribution results were expressed as a percent of injected dose per gram of tissue (%ID/g). Aortic lesion and control uptakes were defined as the average uptake in all segments ranked (ϩϩϩ) or (Ϫ), respectively. Lesion-to-control, lesion-to-blood, and lesion-to-heart ratios were also determined. Adjacent 20-m and 8-m-thick cryosections were obtained from all 12 aortic segments for microautoradiography imaging (BASS-5000, Fujifilm) and immunohistological VCAM1 staining, respectively.
Competition
Biodistribution of 99m Tc-cAbVCAM1-5 in ApoE Ϫ/Ϫ mice was assessed by in vivo SPECT/CT imaging and ex vivo ␥-well counting with (nϭ6) or without (nϭ4) coinjecting a 100-fold excess of unlabeled competitor nanobody cAbVCAM1-1. Results are expressed in %ID/g.
Pharmacodynamics
A subgroup of C57Bl/6J mice was used to evaluate 99m TccAbVCAM1-5 pharmacodynamics in major organs using dynamic SPECT/CT imaging from 0 -180 minutes after injection (86.1Ϯ28.0 MBq) (nϭ3). Results are expressed as %ID/cm 3 .
Blood Kinetics
99m Tc-cAbVCAM1-5 blood clearance was assessed in C57BL/6J mice (nϭ3) by collecting blood samples at several time points after injection. Results are expressed as %ID in total blood volume (%ID/TBV).
Immunohistochemistry
Primary anti-VCAM1 antibody (Santa-Cruz Biotechnology) was applied overnight at 4°C, biotinylated secondary antibody (Jackson ImmunoResearch) was incubated for 1 hour at 20°C, and DAB was used as the chromogen. Staining specificity was assessed by omitting the primary antibody. In a subset of ApoE Ϫ/Ϫ and control mice, VCAM1 immunostaining was also performed on heart, muscle, salivary gland, liver, bone marrow, lymph node, spleen, and thymus.
SPECT/CT Imaging
Two hours after intravenous injection, anesthetized animals were placed in a temperature-controlled bed and whole-body SPECT/CT acquisitions were performed from 2-3 hours after injection (nano-SPECT, Bioscan). CT and SPECT acquisitions were reconstructed, fused, and quantified using dedicated software (InVivoScope). SPECT scale was normalized to %ID/cm 3 to allow direct visual comparison between animals. Regions of interest (ROIs) were drawn at the level of the aortic arch and left ventricle cavity for determination of arch-to-blood ratio.
Autoradiography
For each animal, autoradiographic images were obtained after overnight exposure of 3 sets of 20-m-thick slices obtained at distinct levels of the 12 aortic segments. Images were quantified using dedicated software (Image Gauge, Fujifilm). ROIs were drawn around atherosclerotic lesions and control VCAM1-negative aortic wall. Results were corrected from background and expressed as average lesion-to-control ratios.
Statistical Analysis
All results are presented as meanϮSEM. Nonparametric MannWhitney U, Wilcoxon, and Spearman tests were used to compare unpaired datasets, paired datasets, and correlations between aortic uptake and lesion extension, respectively. Differences were considered significant for PϽ0.05.
Results
Generation of Anti-VCAM1 Nanobodies
To make future clinical translation possible, we aimed at developing nanobodies cross-reactive for mouse and human VCAM1. Nanobodies were therefore generated by immunizing a dromedary with both mouse and human VCAM1 recombinant proteins followed by biopannings of the resulting phage-displayed immune nanobody library. Crude bacterial extracts containing individual nanobodies were screened by ELISA for binding to VCAM1 recombinant proteins and in flow cytometry to bind to VCAM1-expressing bEND5 cells (data not shown).
On sequencing, 31 different anti-VCAM1 nanobodies were identified that could be grouped into 12 families, based on similar sequences in antigen-binding loops. Six nanobody families were mouse VCAM1 (mVCAM1)-specific and 6 families bound to both mouse and human VCAM1 (hV-CAM1). Based on ELISA and flow cytometry signals of crude extracts, 10 nanobodies (called cAbVCAM1-1 to cAbVCAM1-10) were selected for further studies. Nanobody production yield ranged from 0.8 -10.5 mg/L bacterial culture (Table 1) . cAbBcII10, binding to a bacterial enzyme, 18 was used as a nontargeting control nanobody in further comparative experiments.
In Vitro Characterizations
Flow cytometry analysis of mouse bEND5 and human HUVEC endothelial cells stained with an anti-VCAM1 antibody showed low basal VCAM1 expression that was strongly elevated on TNF␣ treatment ( Figure 1A and 1B). Under these conditions, all 10 selected nanobodies interacted with mV-CAM1 on stimulated bEND5 cells ( Figure 1A ). Among them, 6 were found to be cross-reactive for hVCAM1 expressed on stimulated HUVECs ( Figure 1B) . As demonstrated by SPR analyses summarized in Table 1 and as exemplified in Figure  1C , all selected nanobodies bound to mVCAM1 with high affinities ranging from 0.2-45.7 nmol/L. Moreover, in accordance with that observed by flow cytometry, 6 nanobodies were found cross-reactive for hVCAM1 with affinities remaining in the nanomolar range (Table 1) . No binding to the related adhesion receptor ICAM1 was observed for any anti-VCAM1 nanobody, and the control nanobody cAbBcII10 did not bind to VCAM1 in SPR studies. Based on SPR competition studies (Online Figure II) , cAbVCAM1 nanobodies could be grouped into 3 epitope-targeting categories: cAbVCAM1-1/5, cAbVCAM1-2/3/6/7/9/10, and cAbVCAM1-4/8. All nanobodies exhibited high thermal stability as demonstrated by unfolding temperatures ranging from 59.4°C to Ͼ87°C (Table 1) .
After 99m Tc-radiolabeling and purification steps, radiochemical purities were Ͼ95% for all nanobodies.
99m Tclabeling did not affect VCAM1 recognition for most binders as demonstrated by the in vitro binding assay on bEND5 cells ( Figure 1D ): besides cAbVCAM1-8, binding on VCAM1-positive, TNF␣-stimulated cells was significantly higher than on unstimulated cells. Moreover, binding on TNF␣-stimulated cells was successfully inhibited by competition with an excess of unlabeled nanobody and binding of the negative control cAbBcII10 to either stimulated or untreated cells was negligible, thereby demonstrating specificity.
Immunohistochemistry and Biodistribution Analyses
As depicted in Figure 2 , VCAM1 constitutive expression was observed in lymphoid tissues (ie, bone marrow, lymph node, spleen, and thymus) in both C57Bl/6J control and hypercholesterolemic ApoE Ϫ/Ϫ mice, whereas no VCAM1 expression was found in heart, muscle, and salivary gland. VCAM1 staining was also found in ApoE Ϫ/Ϫ mice liver. Moreover, strong VCAM1 staining was also observed within aortic lesions at the level of the luminal endothelium as well as inside the atherosclerotic plaque but not in the aorta of control C57Bl/6J mice.
Biodistributions of 99m Tc-labeled nanobodies in ApoE Ϫ/Ϫ mice are summarized in Online Table I . All nanobodies, including control cAbBcII10, exhibited high kidney uptake ranging from 97Ϯ16 to 315Ϯ33%ID/g and high activities in the bladder. As expected, 99m Tc-cAbVCAM1 uptakes in VCAM1-positive tissues were higher than that of the nontargeting control 99m Tc-cAbBcII10, a difference which reached statistical significance for 99m Tc-cAbVCAM1-3 (spleen and thymus), 99m Tc-cAbVCAM1-4/5 (spleen, thymus, liver and bone marrow), and 99m Tc-cAbVCAM1-9 (thymus and liver), and 99m Tc-cAbVCAM1-1/8/10 (liver) (PϽ0.05 versus 99m TccAbBcII10). With the exception of the lung (mean uptake of 2.5Ϯ0.8%ID/g), uptake was lower than 2%ID/g in other investigated tissues, including the blood and myocardium.
Aortas from hypercholesterolemic ApoE Ϫ/Ϫ mice injected with 99m Tc-labeled nanobodies were segmented and samples were macroscopically scored according to relative lesion content. As shown in Table 1 , uptake in atherosclerotic lesions was greater than 2%ID/g for 6 of 10 cAbVCAM1, with a maximum value of 2.99Ϯ0.07%ID/g for 99m TccAbVCAM1-9 (PϽ0.05 versus 99m Tc-cAbBcII10), whereas MeanϮSEM values and rank (#) are given for parameters obtained either ex vivo by gamma-well counting (%ID/g lesion, lesion-to-control ratio, lesion-to-blood ratio, lesion-to-heart ratio) or in vitro (K D for mVCAM1 or hVCAM1, production yield and T m ). cAbVCAM1-5 is the most potent candidate, based on these criteria. *PϽ0.05 versus cAbBcII10.
the lowest uptake was noted for the nontargeting control 99m Tc-cAbBcII10. Lesion-to-control, lesion-to-blood, and lesion-to-heart ratios were determined from biodistribution data ( Table 1) . Lesion-to-control ratios were Ͼ2 for all VCAM1-specific nanobodies with the exception of 99m Tc-cAbVCAM1-8, with a maximum ratio of 4.95Ϯ0.85 for 99m Tc-cAbVCAM1-5 (PϽ0.05 versus 99m Tc-cAbBcII10). Lesion-to-blood ratio was Ͼ1 for 9 of 10 99m Tc-cAbVCAM1 nanobodies, with a maximum ratio of 5.06Ϯ0.39 for 99m Tc-cAbVCAM1-3 (PϽ0.05 versus 99m Tc-cAbBcII10). Finally, lesion-to-heart ratio was Ͼ1 for all nanobodies, with a maximum value of 8.30Ϯ1.11 for 99m Tc-cAbVCAM1-5 (PϽ0.05 versus 99m Tc-cAbBcII10).
Further Evaluations of the Lead Nanobody cAbVCAM1-5
Based on selection criteria summarized in Table 1 , cAbVCAM1-5 was selected among the 10 evaluated anti-VCAM1 nanobodies for further investigations and compared with nontargeting control 99m Tc-cAbBcII10.
Stability
As demonstrated by HPLC, 99m Tc-cAbVCAM1-5 was stable in vitro for up to 6 hours after radiolabeling, as well as in vivo in the blood at 3 hours after injection, after completion of SPECT imaging ( Figure 3A through 3C) . Biodistribution 99m Tc-cAbVCAM1-5 rapidly cleared from the circulation and background tissues (Online Figure III) and uptake in kidneys, bladder, and VCAM1-positive lymphoid tissues was clearly identifiable on in vivo SPECT images from control C57Bl/6J mice, whereas only the kidneys and bladder were visible after the injection of the nontargeting control 99m Tc-cAbBcII10 ( Figure 3D and 3E) .
99m Tc-cAbVCAM1-5 uptake in lymphoid tissues was further confirmed ex vivo by biodistribution analyses (Table 2) . Indeed, 99m Tc-cAbVCAM1-5 uptake represented 7.4Ϯ0.2, 1.5Ϯ0.1 and 7.9Ϯ2.0%ID/g in spleen, thymus, and bone marrow of control mice, respectively (PϽ0.05 versus nontargeting control 99m Tc-cAbBcII10). Furthermore, 99m Tc-cAbVCAM1-5 biodistribution in ApoE Ϫ/Ϫ mice major organs was similar to that observed in C57Bl/6J mice ( Table 2 , PϭNS). 
Uptake in Atherosclerotic Lesions
In ApoE Ϫ/Ϫ mice, 99m Tc-cAbVCAM1-5 aortic uptake correlated with the lesion-extension index. Indeed, 99m TccAbVCAM1-5 uptake in individual aortic segments increased together with the relative volume of the atherosclerotic lesion, whereas no such gradient was observed for 99m Tc-cAbBcII10 (Spearman ϭ0.894; PϽ0.0001; Figure  4A ).
99m Tc-cAbVCAM1-5 uptake in the aorta was further characterized using autoradiography of sections. As shown in Figure 4B and Online Figure IV, 99m Tc-cAbVCAM1-5 accumulated within VCAM1-positive atherosclerotic lesions, resulting in a lesion-to-control ratio of 8.7Ϯ0.8 (PϽ0.05 versus cAbBcII10).
After SPECT/CT imaging, 99m Tc-cAbVCAM1-5 uptake was readily visualized on atherosclerotic lesions from the aortic arch of hypercholesterolemic ApoE Ϫ/Ϫ mice, whereas no tracer uptake was observed at the same location in control C57Bl/6J animals or with the nontargeting control 99m TccAbBcII10 in either mouse strain ( Figure 5A ). As a result, the 99m Tc-cAbVCAM1-5 aortic arch-to-blood ratio from ApoE Ϫ/Ϫ mice was significantly higher than that observed in C57Bl/6J animals or than that obtained after injection of the nontargeting control nanobody (PϽ0.05) ( Figure 5B ). Finally, coinjection with an excess of unlabeled cAbVCAM1-1, a nanobody recognizing the same VCAM1-epitope as Figure 2 . VCAM1 expression was observed in lymphoid tissues (ie, bone marrow, lymph nodes, spleen, and thymus) of both C57Bl/6J control and hypercholesterolemic ApoE ؊/؊ mice via immunohistochemistry, whereas no VCAM1 expression was found in heart, muscle, and salivary glands. VCAM1 expression was also found in ApoE Ϫ/Ϫ mouse liver. Furthermore, strong VCAM1 expression was observed within aortic lesions, at the level of the endothelium, as well as inside the atherosclerotic plaque. The specificity of these results was demonstrated by the absence of staining on control slices where primary antibody was omitted. Scale bars: 20 m, except for aorta (100 m). Figure II, B) , resulted in significant decrease in 99m Tc-cAbVCAM1-5 uptake in liver, lymphoid tissues, and atherosclerotic lesions, thereby demonstrating specificity of the signals ( Figure 6 ).
cAbVCAM1-5 (Online
Discussion
This study was designed to generate nanobodies recognizing both mouse and human VCAM1 homologues, since such cross-reactive binders would be suitable for translation into clinical practice after validation in well-characterized animal models. Ten anti-mVCAM1 nanobodies, including 6 nanobodies cross-reactive with hVCAM1, were successfully generated and produced with affinities for mouse and/or human homologue in the nanomolar range. The elevated heat resistance of all tested nanobodies allowed 99m Tc radiolabeling at 50°C with high radiochemical purity (Ͼ95%). Furthermore, in vitro binding assays on VCAM1-positive mouse endothelial cells revealed that all cAbVCAM1 remained specific mVCAM1-binders after 99m Tc-labeling, with the exception of cAbVCAM1-8. As expected, due to their small size, nanobodies exhibited fast blood clearance in vivo, resulting in a mean circulating activity of 0.8%ID/g at 3 hours after injection in ApoE Ϫ/Ϫ mice (range, 0.3-1.5%ID/g). In addition, myocardial background activity was also minimal (mean, 0.4%ID/g; range, 0.3-1.5). These biodistribution kinetics are in accordance with those previously obtained using anti-epidermal growth factor receptor and anti-HER2 99m Tclabeled nanobodies. 3, 5 More importantly, cAbVCAM1 nanobody uptake in aortic atherosclerotic lesions was higher than that of a nontargeting control nanobody cAbBcII10, and this difference reached statistical significance for 8 of the 10 evaluated nanobodies. Consequently, with the exception of cAbVCAM1-1, lesion-to-control, lesion-to-blood, and lesionto-heart ratios were all Ͼ1, with mean ratios of 3.2, 2.9, and 5.6, respectively.
Uptake in VCAM1-Positive Tissues
In addition to the expected uptake in atherosclerotic lesions, most cAbVCAM1 nanobodies were taken up by lymphoid tissues in both normal and hypercholesterolemic mice, as demonstrated by biodistribution and in vivo SPECT imaging experiments. More specifically, the 5 cAbVCAM1 nanobodies presenting with the highest affinities for mVCAM1 (cAbVCAM1-2/3/4/5/9, all K D Ͻ2.5 nmol/L) exhibited the highest uptakes in the spleen and bone marrow. Corresponding mVCAM1 constitutive expression was observed by immunohistochemistry in spleen, bone marrow, lymph nodes, and thymus. Therefore, cAbVCAM1 binding to lymphoid Tc-cAbVCAM1-5 was taken up at the level of the bladder (Bl) and kidneys (Kd) as well as in the lymphoid tissues: lymph nodes (LN), bone marrow (BM), thymus (Tm), and spleen (Sp). Table 2 tissues was likely due to specific VCAM1 binding in vivo. VCAM1 constitutive expression in lymphoid tissues has been previously reported by others, either in mouse bone marrow, 19 spleen, 20 lymph nodes, 21 and thymus 22 or in human thymus, 23 bone marrow, and fetal or activated spleen. 24 Furthermore, specific uptake of radiolabeled anti-VCAM1 antibodies in mouse lymphoid organs has also been demonstrated previously. 25, 26 Finally, an increase in the liver activity of several cAbVCAM1 nanobodies was observed, in accordance with the hepatic expression of VCAM1 that was evidenced in ApoE Ϫ/Ϫ animals in the present study and elsewhere. 27 
Selection of Lead Compound
Based on the parameters summarized in Table 1 , cAbVCAM1-5 was selected as the lead compound among 10 evaluated anti-VCAM1 nanobodies. Indeed, cAbVCAM1-5 exhibited the highest lesion-to-control and lesion-to-heart ratios, as well as a high lesion-to-blood ratio. In addition, cAbVCAM1-5 was cross-reactive with hVCAM1 with nanomolar affinities for both mVCAM1 and hVCAM1 as demonstrated by SPR and flow cytometry experiments, a highly relevant result when considering the future potential clinical evaluation of cAbVCAM1-5. Finally, cAbVCAM1-5 also displayed the highest heat resistance and production yield. The absence of lysine residue in the antigen-binding regions was also a criterion for cAbVCAM1-5 selection, since the presence of lysine could be a potential hurdle for future studies requesting coupling chemistry via amino residues, such as for fluorescent or radiolabeling for positron emission tomography (PET) imaging.
cAbVCAM1-5 In Vivo Imaging
99m Tc-cAbVCAM1-5 was stable in vitro for up to 6 hours after radiolabeling as well as in vivo in mouse blood as demonstrated by HPLC, thereby allowing SPECT/CT imaging at 2-3 hours after injection. At this time point, atherosclerotic lesions located within the aortic arch of ApoE Tc-cAbVCAM1-5 is therefore a suitable radiotracer for the noninvasive in vivo imaging of inflammatory processes occurring in atherosclerotic lesions.
Comparison With Other Radiotracers
Other antibody-derived radiotracers have been evaluated recently for the imaging of vulnerable atherosclerotic plaques using SPECT. 28, 29 However, the slow blood clearance of full-sized antibodies resulted in suboptimal target-tobackground ratios, therefore emphasizing the need to use antibody fragments (Fab, scFv) or engineered variants. Among the other radiotracers previously evaluated for SPECT or PET imaging of atherosclerotic lesions, 18 FDG exhibited an elevated uptake in macrophages, thereby allowing in vivo imaging of carotid lesions in humans. 30 However, due to high myocardial background, imaging of coronary lesions remains extremely challenging despite the potential use of a specific diet aimed at lowering myocardial uptake. 31 Similarly, in a mouse model of atherosclerosis, Laitinen et al found that 18 FDG myocardial uptake was 18.13Ϯ10.59%ID/g in comparison to 0.41Ϯ0.16%ID/g in atherosclerotic lesions at 1 hour after injection. 32 18 F-4V, a VCAM1-targeting peptide-based tracer, has recently been evaluated for PET imaging of vulnerable lesions in mice. 15 Interestingly and similarly to that observed in the present study, 18 F-4V uptake was elevated in VCAM1-expressing tissues such as the lymph nodes and spleen and to a lower extent in the thymus (3.7Ϯ0.3, 2.1Ϯ0.6, and 0.9Ϯ0.3%ID/g at 4 hours after injection, respectively); however, the potential specificity of this binding was not further discussed by the authors. Advantages of the 99m Tc-labeled nanobody cAbVCAM1-5 over 18 F-4V include a more than 40-fold higher affinity for mVCAM1, since the IC 50 of 18 F-4V was 86.6 nmol/L, whereas cAbVCAM1-5 kD was 2.0Ϯ0.0 nmol/L. Of note, 18 F-4V affinity for hVCAM-1 has not been reported yet. 99m Tc-cAbVCAM1-5 also exhibited a lower uptake at 3 hours after injection than 18 F-4V at 4 hours after injection in background tissues such as the blood (0.5Ϯ0.1 versus 1.5Ϯ0.4%ID/g), myocardium (0.2Ϯ0.0 versus 0.6Ϯ0.2%ID/ g), and control aorta (0.6Ϯ0.1 versus 1.3Ϯ0.4%ID/g), resulting in a more favorable lesion-to-control ratio in ApoE 
Limitations of Nanobody Methodology and Clinical Translatability
Immunization of a camelid with a target protein of interest probably remains a necessary step because nanobodies from naive or synthetic libraries are mostly of lower affinity. In addition, whereas the obtention of recombinant proteins corresponding to large extracellular domains of type I or II transmembrane receptors can be easily achieved, as is the case for VCAM1, the same does not hold for more complex structures such as heterodimeric receptors or receptors spanning the cellular membrane multiple times.
When produced as recombinant proteins, evident questions arise regarding immunogenicity, toxicity, and safety when nanobody-based tracers are designed for clinical translation. In this regard, it should be noted that several nanobodies, including an anti-von Willebrand Factor nanobody for prevention of the acute coronary syndromes, were already clinically evaluated in phase Ia, Ib, and II clinical trials without demonstrating adverse events and detectable immunogenicity at repeatedly administered therapeutic doses far above the single injected dose that will be used for diagnostic purposes as described in the present study. 33 Also, we are currently running a "first-in man" phase I clinical study with a 68 Ga-labeled anti-HER2 nanobody 5 for PET imaging of breast cancer patients, in which efficacy, safety, and dosimetry will be the monitored parameters. 99m Tc-cAbVCAM1-5 as tracer for SPECT/CT in vivo imaging of atherosclerotic plaques. A, Representative in vivo SPECT/CT coronal views taken at the level of the aortic arch of C57Bl/6J and ApoE Ϫ/Ϫ mice 2-3 hours after intravenous injection of 99m Tc-cAbBcII10 or 99m Tc-cAbVCAM1-5 nanobodies. The scale was adjusted from 1-3.4% of the injected dose to allow direct visual comparison. Focal uptake of 99m TccAbVCAM1-5 was visible in the axillary lymph nodes (ln) and thymus (t) of both C57Bl/6J and ApoE Ϫ/Ϫ mice. In addition, 99m Tc-cAbVCAM1-5 uptake in atherosclerotic lesions from ApoE Ϫ/Ϫ mice was also clearly identifiable at the level of the aortic arch (ao). B, In vivo determination of arch-to-blood ratios based on SPECT image quantifications. This ratio was significantly higher in atherosclerotic ApoE Ϫ/Ϫ than control C57Bl/6J mice for 99m Tc-cAbVCAM1-5 (nϭ6 and 4, respectively) but not for the negative control 99m Tc-cAbBcII10 (nϭ4 and 5, respectively). *PϽ0.05 versus 99m Tc-cAbBcII10, †PϽ0.05 versus C57BL/6J. 99m Tc-cAbVCAM1-5 was injected in ApoE Ϫ/Ϫ mice either alone (nϭ4) or together with a 100-fold excess of unlabeled competitor cAbVCAM1-1 (nϭ6). A, Representative SPECT/CT images. B, ex vivo biodistribution at 3 hours after injection Competition resulted in significant decreases of 99m Tc-cAbVCAM1-5 uptake in liver, lymphoid tissues, and atherosclerotic lesions, thereby demonstrating specificity of the signals. *PϽ0.05 versus no competition.
Conclusions and Perspectives
Unlike anatomic imaging methodologies, which are confronted with strong resolution requirements to distinguish distinct plaque components for the identification of vulnerable lesions based on the size of the necrotic core or the thickness of the fibrous cap, the challenges associated with atherosclerosis molecular imaging are strongly related to the sensitivity of the detection systems. Nuclear imaging presents an exquisite, femtomolar sensitivity that is well suited for the molecular imaging of atherosclerotic lesions. This study evaluated for the first time the potential of nanobodies as radiotracers dedicated to nuclear cardiology. When taken into perspective with previously published results related to tumor imaging, our results confirm that nanobodies constitute a promising new class of radiotracers with great potential for noninvasive nuclear imaging.
In the present study, 10 anti-VCAM1 nanobodies were evaluated. Procedures were carefully designed to generate nanobodies cross-reactive for hVCAM1 protein.
99m TccAbVCAM1-5 was selected as the most potent candidate for the development of a new radiopharmaceutical for noninvasive imaging of vulnerable atherosclerotic lesions. In ApoE Ϫ/Ϫ atherosclerotic mice, VCAM1-positive lesions were successfully identified by SPECT/CT imaging using the human and mouse cross-reactive 99m Tc-cAbVCAM1-5, thereby demonstrating a strong potential for clinical translation.
In addition to high production yield, high stability, and fast blood clearance, nanobodies engineering offers a number of advantages. Specifically, successful radiolabeling of nanobodies with a positron emitter was recently described, 2 as well as labeling of nanobodies with near infrared dyes 34 and coupling to microbubbles 35 or Gadolinium vesicles, 36 hereby allowing the use of SPECT, PET, optical, ultrasound, or MRI systems with nanobody-based tracers. In addition, humanized and bivalent nanobodies can easily be generated. 4, 37 In particular, further studies will be conducted to evaluate the performances of bivalent cAbVCAM1 constructs targeted at 2 distinct epitopes as well as the potential of 68 Ga-or 18 F-labeled cAbVCAM1-5 for PET imaging of atherosclerotic lesions.
